These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection. Roberts LM; Davies JS; Sempowski GD; Frelinger JA Vaccine; 2014 Jun; 32(29):3595-603. PubMed ID: 24837506 [TBL] [Abstract][Full Text] [Related]
23. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Chen W; Shen H; Webb A; KuoLee R; Conlan JW Vaccine; 2003 Sep; 21(25-26):3690-700. PubMed ID: 12922099 [TBL] [Abstract][Full Text] [Related]
24. Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells. Griffin AJ; Crane DD; Wehrly TD; Bosio CM Clin Vaccine Immunol; 2015 Jan; 22(1):119-28. PubMed ID: 25410207 [TBL] [Abstract][Full Text] [Related]
25. A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice. Quarry JE; Isherwood KE; Michell SL; Diaper H; Titball RW; Oyston PC Vaccine; 2007 Mar; 25(11):2011-8. PubMed ID: 17241711 [TBL] [Abstract][Full Text] [Related]
26. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine. Kim TH; Pinkham JT; Heninger SJ; Chalabaev S; Kasper DL J Infect Dis; 2012 Apr; 205(7):1056-65. PubMed ID: 21969334 [TBL] [Abstract][Full Text] [Related]
27. Preclinical testing of a vaccine candidate against tularemia. Suresh RV; Ma Z; Sunagar R; Bhatty V; Banik S; Catlett SV; Gosselin EJ; Malik M; Bakshi CS PLoS One; 2015; 10(4):e0124326. PubMed ID: 25897786 [TBL] [Abstract][Full Text] [Related]
28. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. Chu P; Cunningham AL; Yu JJ; Nguyen JQ; Barker JR; Lyons CR; Wilder J; Valderas M; Sherwood RL; Arulanandam BP; Klose KE PLoS Pathog; 2014 Oct; 10(10):e1004439. PubMed ID: 25340543 [TBL] [Abstract][Full Text] [Related]
29. Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. Rockx-Brouwer D; Chong A; Wehrly TD; Child R; Crane DD; Celli J; Bosio CM PLoS One; 2012; 7(5):e37752. PubMed ID: 22662210 [TBL] [Abstract][Full Text] [Related]
30. Deletion of IglH in virulent Francisella tularensis subsp. holarctica FSC200 strain results in attenuation and provides protection against the challenge with the parental strain. Straskova A; Cerveny L; Spidlova P; Dankova V; Belcic D; Santic M; Stulik J Microbes Infect; 2012 Feb; 14(2):177-87. PubMed ID: 21930232 [TBL] [Abstract][Full Text] [Related]
31. Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns. Mares CA; Ojeda SS; Morris EG; Li Q; Teale JM Infect Immun; 2008 Jul; 76(7):3001-10. PubMed ID: 18411294 [TBL] [Abstract][Full Text] [Related]
32. Characterization of Schu S4 Cunningham AL; Mann BJ; Qin A; Santiago AE; Grassel C; Lipsky M; Vogel SN; Barry EM Virulence; 2020 Dec; 11(1):283-294. PubMed ID: 32241221 [TBL] [Abstract][Full Text] [Related]
33. Francisella tularensis type B ΔdsbA mutant protects against type A strain and induces strong inflammatory cytokine and Th1-like antibody response in vivo. Straskova A; Spidlova P; Mou S; Worsham P; Putzova D; Pavkova I; Stulik J Pathog Dis; 2015 Nov; 73(8):ftv058. PubMed ID: 26253078 [TBL] [Abstract][Full Text] [Related]
34. Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Anderson RV; Crane DD; Bosio CM Vaccine; 2010 Sep; 28(40):6562-72. PubMed ID: 20688042 [TBL] [Abstract][Full Text] [Related]
35. Aim2 and Nlrp3 Are Dispensable for Vaccine-Induced Immunity against Francisella tularensis Live Vaccine Strain. Alqahtani M; Ma Z; Fantone K; Malik M; Bakshi CS Infect Immun; 2021 Jun; 89(7):e0013421. PubMed ID: 33875472 [TBL] [Abstract][Full Text] [Related]
36. Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model. Stinson E; Smith LP; Cole KS; Barry EM; Reed DS Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27511964 [TBL] [Abstract][Full Text] [Related]
37. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Li J; Ryder C; Mandal M; Ahmed F; Azadi P; Snyder DS; Pechous RD; Zahrt T; Inzana TJ Microbiology (Reading); 2007 Sep; 153(Pt 9):3141-3153. PubMed ID: 17768257 [TBL] [Abstract][Full Text] [Related]
38. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Jia Q; Lee BY; Clemens DL; Bowen RA; Horwitz MA Vaccine; 2009 Feb; 27(8):1216-29. PubMed ID: 19126421 [TBL] [Abstract][Full Text] [Related]
39. Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Qin A; Scott DW; Thompson JA; Mann BJ Infect Immun; 2009 Jan; 77(1):152-61. PubMed ID: 18981253 [TBL] [Abstract][Full Text] [Related]
40. Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. Signarovitz AL; Ray HJ; Yu JJ; Guentzel MN; Chambers JP; Klose KE; Arulanandam BP PLoS One; 2012; 7(10):e47639. PubMed ID: 23118885 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]